- Medical School - University of Tennessee Center for the Health Sciences (2004-2009)
- Residency - UT Southwestern Medical Center (2009-2014)
- Fellowship - Memorial Sloan Kettering Cancer Center (2014-2016), Urologic Oncology
Aditya Bagrodia, M.D.
- Dedman Family Scholar in Clinical Care
- Testicular Cancer
- Bladder Cancer
Aditya Bagrodia, M.D., is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, where he is the Dedman Family Scholar in Clinical Care.
Dr. Bagrodia holds a bachelor of science degree from Rhodes College. While earning a medical degree with highest honors at the University of Tennessee Health Sciences Center, he was awarded a Doris Duke Clinical Research Fellowship at UT Southwestern Medical Center.
After completing his residency in urology at UT Southwestern, he received advanced training in urologic oncology through a fellowship at Memorial Sloan Kettering Cancer Center, where he was awarded a Urology Care Foundation Research Scholars Grant by the American Urological Association.
Dr. Bagrodia’s clinical practice focuses on treating all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.
Dr. Bagrodia has conducted extensive
research in urologic oncology, primarily in biomarker profiles and molecular
signatures of urologic tumors as predictors of clinical outcomes. He is funded
through competitive grants from the Cancer Prevention and Research Institute of
Texas (CPRIT), intramural research grants, and the National Institutes of
Both his clinical practice and research centers on patients with germ cell tumors (most commonly testicular cancer). His laboratory focuses on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors and identifying novel biomarkers to recognize occult metastatic disease. The Bagrodia lab also conducts experiments in cell lines, zebrafish germ cell tumor models, and mice to understand the biologic implications of genetic alterations that are seen exclusively among patients with cisplatin-resistance disease. He is actively working on molecular biomarkers to identify minimal residual disease burden. On the clinical side, Dr. Bagrodia is actively involved in understanding and overcoming unique socioepidemiologic considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials at UT Southwestern (including NCT03426865 and NCT02537548).
Dr. Bagrodia is the principal author or co-author of more than 100 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. He is also a reviewer for many of these publications, as well as for the British Journal of Urology, Journal of Clinical Pathology, and Annals of Surgical Oncology.
Meet Dr. Bagrodia
Urologist in Dallas
A diagnosis of urologic cancer means tough decisions. While treatment options are varied, they can have long-term effects on sexual function, continence, and overall health. UT Southwestern urologist Aditya Bagrodia, M.D., guides his patients on a path that’s best for them – both in terms of survival and quality of life – including navigating the latest treatments.
For example, Dr. Bagrodia says there is no cancer in genitourinary oncology in which the decisions are more complex and challenging than testicular cancer.
“Given the high cancer-specific survival rates and relatively young age at presentation for these young cancer victims, I am interested in maximizing efficacy and minimizing morbidity of unnecessary treatment,” he says. “UT Southwestern offers a comprehensive testicular germ cell tumor program that provides nerve-sparing surgery, the most innovative minimally invasive surgical techniques, and incorporating novel imaging platforms and molecular biomarkers to help make individualized treatment decisions.”
Patients with newly diagnosed prostate cancers also face choices, Dr. Bagrodia says.
“Is it appropriate and safe to wait and see if a tumor becomes aggressive? Or would it be better to proceed with surgery, radiation, or participation in clinical trials of a new therapy? As we learn more about the nature of cancer, we can help each patient make highly personalized treatment decisions,” he says.
Men whose prostate cancers are considered indolent (non-aggressive) and pose a low risk may choose active surveillance – informally known as watchful waiting – rather than immediate treatment. These patients are closely monitored at regular intervals in UT Southwestern’s MRI fusion-guided biopsy program to make sure their cancer is not changing into a more aggressive form.
When prostate cancer patients want to have a tumor removed as promptly as possible, Dr. Bagrodia says robotic surgery will be a key component of their treatment plan.
“We combine an evaluation of the disease biology with state-of-the-art imaging,” he says. “This allows us to design the surgery to achieve an optimal cancer outcome while minimizing damage to nerves and healthy tissue that are important for urinary continence.”
Whatever the particular condition and the ultimate treatment plan, a collaborative approach to care is essential.
“Successful treatment for urologic malignancies draws not only on the individual physician’s skill, but on the close collaboration among multiple specialties, such as medical oncology and radiation oncology,” Dr. Bagrodia says. “We have excellent capabilities in all of these disciplines here at UT Southwestern. And we have constant, collegial communication across the team and at every stage of a patient’s care.”
Researching the Next Generation of Treatments
Urologic cancers are found not only within male sex organs; they also encompass cancers of the bladder and kidney. With their vague and ambiguous symptoms, these malignancies are, unfortunately, rarely diagnosed early in the disease process; when they are, it’s usually because they have been discovered during tests for other conditions.
Dr. Bagrodia and his colleagues are studying ways to evaluate bladder and kidney cancers more quickly and accurately through MRI imaging techniques and molecular analysis. Such insights will facilitate customized treatments that may include radiation, robotic techniques, and surgical ablation.
Patients with aggressive bladder or kidney cancers have access to leading-edge, organ-sparing surgical approaches whenever feasible, as well as neobladder construction for both male and female patients when appropriate.
“Our patients are understandably quite anxious about their diagnosis and choosing the treatments that are right for them,” Dr. Bagrodia says. “What I find most gratifying about my practice is not only meeting the medical challenges of treating urologic cancers. It’s also about walking my patients through the experience, making sure they understand their options, and easing their minds that they are receiving the best care.”
- Testicular Cancer
- Bladder Cancer
- Prostate Cancer
- Surgery for Genitourinary Cancer
- Genitourinary Cancer
- Kidney Cancer